| (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations (NCT05241873) | Blueprint Medicines Corporation | 2022-03-04 |
| (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC (NCT05153408) | Blueprint Medicines Corporation | 2022-01-13 |
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC (NCT04862780) | Blueprint Medicines Corporation | 2021-06-29 |
| Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) (NCT04776447) | Fundación GECP | 2021-06-16 |
| External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC (NCT04697446) | Blueprint Medicines Corporation | 2020-12-01 |
| A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT04222972) | Hoffmann-La Roche | 2020-07-24 |
| A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC (NCT03134872) | Jiangsu HengRui Medicine Co., Ltd. | 2017-05-12 |
| International Lung Screen Trial (ILST) (NCT02871856) | The University of Queensland | 2017-04-05 |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (NCT03037385) | Hoffmann-La Roche | 2017-03-17 |
| Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (NCT02909452) | Syndax Pharmaceuticals | 2016-09-20 |
| Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors (NCT02897778) | Syndax Pharmaceuticals | 2016-08-24 |
| Alberta Lung Cancer Screening Program (NCT02431962) | University of Calgary | 2015-04-01 |
| The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial (NCT03402048) | University of Turin, Italy | 2012-07-01 |
| A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer (NCT01039948) | AVEO Pharmaceuticals, Inc. | 2009-12-01 |
| High Dose Somatostatin Analogues in Neuroendocrine Tumors (NCT00990535) | Federico II University | 2006-01-01 |
| Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC (NCT06841874) | Nuvation Bio Inc. | |